Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics Inc (WINT) delivers innovative therapies targeting acute heart failure and respiratory distress through its pioneering SERCA2a activation technology and KL4 surfactant platform. This news hub provides investors and industry professionals with centralized access to the company's latest developments.
Key updates include: Clinical trial progress for istaroxime in cardiogenic shock, regulatory milestones for neonatal respiratory treatments, strategic licensing agreements, and financial performance reports. Our curated news collection eliminates the need to monitor multiple sources, offering timestamped updates directly from company releases and verified industry reports.
Regularly updated content covers Phase 2/3 trial results, intellectual property expansions, partnership announcements with pharmaceutical leaders, and analysis of market-moving events. Bookmark this page to track how Windtree's dual focus on cardiovascular innovation and surfactant delivery systems positions it in the competitive biotech landscape.
Windtree Therapeutics (NASDAQ: WINT) has provided an update on the clinical development of istaroxime, a novel first-in-class therapy for acute heart failure and early cardiogenic shock. The company is nearing completion of enrollment for its SEISMiC Extension Phase 2b study in early cardiogenic shock patients, with topline data expected by the end of the quarter. The study focuses on dose optimization and SERCA2a effects for Phase 3 planning.
Windtree is also progressing a parallel study in more severe SCAI Stage C cardiogenic shock patients. Additionally, the company has entered a license agreement with Lee's Pharmaceutical for the development and commercialization of istaroxime in Greater China, potentially worth up to $138 million in milestones plus royalties.
Windtree Therapeutics (NASDAQ: WINT) has closed a $12.9 million private placement of Series C Convertible Preferred Stock and warrants. The transaction includes $3.4 million in new funding and $9.5 million in debt cancellation. Additionally, the company established a $35 million equity line of credit.
The private placement involved issuing 16,099 shares of Series C Preferred Stock and warrants to acquire up to 3,440,631 additional common shares. The warrants have an exercise price of $4.11 per share and will become exercisable after six months.
Windtree plans to use the proceeds for working capital and general corporate purposes. The company is also nearing completion of its Phase 2b clinical trial for istaroxime in cardiogenic shock, with topline data expected by the end of the current quarter.
Windtree Therapeutics, a biotechnology company, regained compliance with Nasdaq's minimum bid price requirement after facing non-compliance due to its common stock price falling below $1 for 30 consecutive trading days. The company took necessary steps to meet the bid price threshold, resulting in compliance with the regulations.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
